Amanda F. Austin
Amanda Austin joined Ropes & Gray in 2005 and practices in the life sciences group. Amanda’s practice primarily focuses on the representation of pharmaceutical, medical device and biotechnology companies and non-profit institutions in intellectual property transactions, including licenses, research and development collaboration agreements, strategic commercial partnerships, joint ventures, co-promotion agreements and distribution and manufacturing arrangements.
- Represented Pfizer in its contribution of assets related to allogeneic chimeric antigen receptor T cell (CAR-T) therapy to Allogene Therapeutics.
- Represented a public university in the sale of a portion of its royalty interest in an orphan drug.
- Assisted multiple clients, including a non-profit institution and a leading pharmaceutical company, with the development of licensing templates for internal use.
- Represented Ironwood Pharmaceuticals in its licensing agreement with AstraZeneca for the U.S. rights to Zurampic, an FDA-approved treatment for hyberuricemia associated with uncontrolled gout.
- Represented Beam Therapeutics in connection with its licenses from Editas Medicine and The Broad Institute.
- Represented Pfizer in its option to acquire AM-Pharma, a private company focused on the development of recombinant human Alkaline Phosphatase (recAP) for the treatment of inflammatory diseases.
- Represented Hutchison MediPharma in a joint venture with Nestle Health Science to research, develop, manufacture and market nutritional products derived from botanical plant origins.
- Represented a leading global biotechnology company in a $300 million joint venture to develop and market biosimilars with a Korea-based company.
- Represented FORMA Therapeutics, Inc. in a drug discovery collaboration with Janssen Pharmaceuticals, Inc. under which FORMA and Janssen agreed to collaborate on drug discovery efforts.
- Represented Acceleron Pharma, Inc. in a joint development and commercialization agreement with Celgene Corporation for a protein therapeutic.
- JD, Harvard Law School, 2005
- AB (Government), cum laude, Harvard University, 2002